The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Emibetuzumab plus ramucirumab: Simultaneous targeting of MET and VEGFR-2 in patients with advanced hepatocellular cancer in a phase 1b/2 study.
 
James J. Harding
No Relationships to Disclose
 
Johanna C. Bendell
No Relationships to Disclose
 
Charles S. Fuchs
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Celgene; Genentech/Roche; Gilead Sciences; Lilly; Macrogenics; MedImmune; MedImmune; Merck; Momenta Pharmaceuticals; Pfizer; Pharmacyclics; Sanofi; Takeda; Vertex
 
Xuejing Wang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Volker Wacheck
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
Travel, Accommodations, Expenses - Lilly
 
Andrew X. Zhu
Consulting or Advisory Role - Eisai